Loading
Tonix Pharmaceuticals Holding Corp. Stock: price and insider trades · United States
2 insiders bought €34k of shares over the last 90 days, the latest by LEDERMAN SETH, filed 31 Aug 2026.
Tonix Pharmaceuticals Holding Corp.: what insiders have been doing
Every trade that managers of Tonix Pharmaceuticals Holding Corp. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in New York City. In the past year (22 October 2025 to 22 October 2026), 5 filings came from 3 insiders.
The flow runs one way only: 2 insiders bought (4 purchases totalling €283k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €194k by Lederman Seth, published on 18 March 2026. On the buying side, the filings list 1 senior executive and 1 chief executive among the declarants.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 31 August 2026, 53 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 5 filings here. Our records for Tonix Pharmaceuticals Holding Corp. go back to 2016, with 59 purchases and 7 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 13.1 m USD and net income of -124.0 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
99
Thresholds
n/a
Buy Volume
€2M
59 ops. · all time
Sell Volume
€132,845
7 ops. · all time
Who traded when
BuySaleSeth Lederman4 buys
Carolyn E. Taylor1 buy
James Treco1 buy
Richard H. Bagger1 buy
Since the insiders bought
- -56.8%Entry US$13.98 · Close 16 Oct 2026 US$6.04
- -55.8%Entry US$13.66 · Close 16 Oct 2026 US$6.04
- -67.2%Entry US$37.98 · Close at T+365 US$12.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tonix Pharmaceuticals Holding Corp. Strong Buy (bullish), based on 4 analysts. Average price target: US$44.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,131 of 26,248 companies
19.5
score / 100
Value1
Quality38
FCF yld-104%
Earn yld-125%
EV/EBITDA·
ROE-82%
Gross mgn49%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.78
Analyst consensus
4 analystsStrong buy
US$22.00Target US$44.25(+666%)US$65.00
Income statement
RevenueUS$13.1M
Gross profitUS$6.5M49% margin
EBITDA-US$122M-931% margin
Net income-US$124M-946.2% margin
Valuation
PER (forward)-0.7x
P/Book0.4x
Beta1.79
Balance sheet & cash
Market capUS$99.1M
Total debtUS$1.3M
Free Cash Flow-US$103.2M
Debt / Equity1%
Profitability & ownership
ROE-81.8%
ROA-46.8%
% insiders0.2%
% institutions56.9%
Last declaration on 31 August 2026
Declarations99 total
2,000 shares@ US$13.790.016% mcap5.8% of flowCommon Stock, $0.001 par valueSEC:0001493152-26-040736:0
Canonical exit: 25 Nov 2026 (T+90)
1,000 shares@ US$12.600.0073% mcap100.0% of flowCommon Stock, par value $0.001SEC:0001999371-26-018494:0
Canonical exit: 18 Nov 2026 (T+90)
1,453 shares@ US$10.9140.0094% mcap100.0% of flowCommon Stock, $0.001 par valueSEC:0001493152-26-032615:0
5,000 shares@ US$12.6213.3% of flowCommon Stock, $0.001 par valueSEC:0001999371-26-007447:0
Canonical exit: 29 Jun 2026 (T+90)
15,000 shares@ US$14.8947.2% of flowCommon Stock, $0.001 par valueSEC:0001999371-26-006235:0
Canonical exit: 16 Jun 2026 (T+90)
418 shares@ US$36.03100.0% of flowCommon Stock, par value $0.001SEC:0001999371-25-011836:0
Canonical exit: 19 Nov 2025 (T+90)
250 shares@ US$36.00100.0% of flowCommon Stock, par value $0.001SEC:0001999371-25-011754:0
Canonical exit: 18 Nov 2025 (T+90)
4,000 shares@ US$21.5518.8% of flowCommon Stock, $0.001 par valueSEC:0001999371-25-006261:0
Canonical exit: 13 Aug 2025 (T+90)
0.812 shares@ US$1.91100.0% of flowCommon Stock, par value $0.001SEC:0001839882-25-012471:0
0.02 shares@ US$0.300.0% of flowCommon Stock, par value $0.001SEC:0001839882-25-012472:0
1 shares@ US$0.15100.0% of flowCommon Stock, par value $0.001SEC:0001839882-25-012474:0
0.02 shares@ €0.1928Common Stock, par value $0.001SEC:0001839882-25-012470:0
0.22 shares@ US$3.300.0% of flowCommon Stock, $0.001 par valueSEC:0001839882-25-011952:1
1 shares@ US$0.150.0% of flowCommon Stock, $0.001 par valueSEC:0001839882-25-011952:2
0.11 shares@ US$1.47100.0% of flowCommon Stock, par value $0.001SEC:0001839882-25-011955:0
5.18 shares@ US$3.380.0% of flowCommon Stock, $0.001 par valueSEC:0001839882-25-011952:0
1 shares0Common Stock, $0.001 par valueSEC:0001839882-25-011949:0
0.04 shares0Common Stock, par value $0.001SEC:0001839882-25-011958:0
20,000 shares@ US$1.710.018% mcap8.0% of flowCommon Stock, $0.001 par valueSEC:0001387131-22-007441:0
Canonical exit: 27 Sept 2022 (T+90)
100,000 shares@ US$0.2455.4% of flowCommon Stock, $0.001 par valueSEC:0001387131-22-003991:0
Canonical exit: 23 Jun 2022 (T+90)
12,000 shares@ US$0.611.5% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-009696:0
Canonical exit: 27 Dec 2021 (T+90)
5,000 shares@ US$1.12100.0% of flowCommon StockSEC:0001387131-21-006089:0
Canonical exit: 23 Aug 2021 (T+90)
16,733 shares@ US$1.322.0% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-003875:0
Canonical exit: 22 Jun 2021 (T+90)
41,322 shares@ US$0.5115.0% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-002884:0
35,000 shares@ US$0.682.1% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-000041:0
Canonical exit: 30 Mar 2021 (T+90)
25 of 99 declarations
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a U.S.-based biopharmaceutical company in the United States that has evolved from a clinical-stage developer into a company with a commercial product and a broader pipeline. Its principal executive offices are in Berkeley Heights, New Jersey. The company was incorporated in 2007 as Tamandare Explorations Inc. and changed its name to Tonix Pharmaceuticals Holding Corp. in 2011. Tonix’s roots are closely tied to the work of Dr. Seth Lederman, who founded the underlying Tonix Pharmaceuticals entity in 2007 and has been a central figure in the company’s development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/tnxp-10k_123125.htm?utm_source=openai))
Tonix’s business model spans several therapeutic areas. The most important near-term asset is TONMYA® (cyclobenzaprine HCl sublingual tablets), which the FDA approved in August 2025 for the treatment of fibromyalgia in adults, followed by a U.S. commercial launch in November 2025. Tonix positions TONMYA as the first new FDA-approved treatment for fibromyalgia in more than 15 years, giving the company a meaningful differentiated entry point in a market with limited treatment alternatives. Beyond that commercial franchise, Tonix maintains a pipeline across pain, psychiatry, infectious disease and rare disease, including TNX-102 SL for major depressive disorder, TNX-1500 in transplant/immunology, TNX-2900 for Prader-Willi syndrome, and TNX-4800 for seasonal prevention of Lyme disease. ([ir.tonixpharma.com](https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of?utm_source=openai))
Read moreShow less
From a competitive standpoint, Tonix remains a small-cap biotech rather than a large diversified pharmaceutical company. Its investment case is therefore less about scale and more about regulatory and clinical execution, intellectual property, and the commercial potential of a first-in-category or first-in-indication product. The company also appears to be broadening its operational footprint, with offices in Berkeley Heights, New Jersey, plus additional locations in Fort Worth, Montreal and Dublin, and an R&D center in Frederick, Maryland. That footprint suggests a company building out both commercialization and research capabilities. ([tonixpharma.com](https://www.tonixpharma.com/contact/?utm_source=openai))
Recent milestones have been dominated by product launch and pipeline progress. In 2025, Tonix secured FDA approval for TONMYA and then moved into commercial availability. In 2026, it reported publications supporting the product’s pharmacokinetic profile, expanded payer coverage, and continued advancing clinical programs, including TNX-1500 and TNX-2900. For investors, TNXP is best viewed as a NASDAQ-listed U.S. biotech with a near-term commercial catalyst in TONMYA and a pipeline that could create additional optionality if clinical and regulatory execution stays on track. ([ir.tonixpharma.com](https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of?utm_source=openai))
